

VW
8.5.10

09700851

PATENT
Docket No.: 019026-000110US
Client Ref. No.: T-400

20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

Please replace the paragraph beginning on page 22, line 18, with the following replacement paragraph.

The compositions containing the present humanized immunoglobulins or a cocktail thereof can be administered for therapeutic or prophylactic treatments. In therapeutic application, compositions are administered to a patient already suffering from Verotoxin ~~producing~~ Producing *E. coli* (VTEC) infection and Hemolytic Uremic Syndrome (HUS), or other toxic manifestations from VT2 antigens, in an amount sufficient to cure or at least partially arrest the toxic syndrome and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." In prophylactic applications, compositions are administered to patients at risk of infection in an amount sufficient to prevent or detectably inhibit such infection and/or toxic manifestation thereof due to VT2 antigens. Amounts effective for such uses depend upon the severity of the disease and the general state of the patient's own immune system, but generally range from 0.1 to 5 mg/kg of immunoglobulin per patient dose being commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is life-threatening or potentially life-threatening situations. In such cases, in view of the minimization of extraneous substances and the lower probability of "foreign substance" rejections which are achieved by the present humanized immunoglobulins of this invention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these immunoglobulins.

VW
8.5.10

Please replace the paragraph beginning on page 23, line ¹⁵17, with the following replacement paragraph.

In particular embodiments, compositions comprising humanized immunoglobulin of the present invention may be used to detect VT2 antigens in Verotoxin ~~producing~~ Producing *E. coli* (VTEC) infection and Hemolytic Uremic Syndrome (HUS) and/or in other infections producing